Maranda Nguyen, DO
Family Medicine · Overland Park, KSNPI 1558866988
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 31.0% of the total.
Across 65 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$361
- Lilly USA, LLC$109
- Corium, LLC$103
- Novo Nordisk$101
- Amgen$74
- Boehringer Ingelheim$70
- plus $347 from 13 others
Across 40 payments — averaging $3751.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$60K
- Ironwood Pharmaceuticals, Inc$54K
- AbbVie$36K
What the payments were for
- Food & beverage$1,166100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $361 |
| Lilly USA, LLC | 6 | $109 |
| Corium, LLC | 6 | $103 |
| Novo Nordisk | 5 | $101 |
| Amgen | 4 | $74 |
| Boehringer Ingelheim | 3 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| AstraZeneca | 3 | $48 |
| Merck | 2 | $36 |
| IBSA Pharma Inc. | 2 | $33 |
| Bayer | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Exeltis, USA Inc. | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$1,166 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 14 | $262 |
| Atorvastatin Calcium | 21 | $211 |
| Levothyroxine Sodium | 21 | $208 |
| Omeprazole | 11 | $194 |
| Losartan Potassium | 13 | $178 |
| Lisinopril | 17 | $154 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Overland Park
- Trystan CrookOverland Park$15K
- Liliana NazarioOverland Park$15K
- Neal EricksonOverland Park$13K
- John HansenOverland Park$13K
- David DobratzOverland Park$13K
- Richard RuizOverland Park$12K
- Timothy TalbertOverland Park$12K
- James RahtoOverland Park$11K
- Mark KahlerOverland Park$11K
- Bradley HarrisonManhattan$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.